Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2
Authors:
- Han Wee OngHOHan Wee Ong
- Xuan YangXYXuan Yang
- Jeffery L. SmithJSJeffery L. Smith
- Sharon Taft-BenzSTSharon Taft-Benz
- Stefanie HowellSHStefanie Howell
- Rebekah J. DickmanderRDRebekah J. Dickmander
- Tammy M. HavenerTHTammy M. Havener
- Marcia K. SandersMSMarcia K. Sanders
- Jason W. BrownJBJason W. Brown
- Rafael M. CouñagoRCRafael M. Couñago
- Edcon ChangECEdcon Chang
- Andreas KrämerAKAndreas Krämer
Open Access
- 2 September 2024
- Vol. 29 (17) , 4158
Abstract
The host kinase casein kinase 2 (CSNK2) has been proposed to be an antiviral target against β-coronaviral infection. To pharmacologically validate CSNK2 as a drug target in vivo, potent and selective CSNK2 inhibitors with good pharmacokinetic properties are required. Inhibitors based on the pyrazolo[1,5-a]pyrimidine scaffold possess outstanding potency and selectivity for CSNK2, but bioavailability and metabolic stability are often challenging. By strategically installing a fluorine atom on an electron-rich phenyl ring of a previously characterized inhibitor 1, we discovered compound 2 as a promising lead compound with improved in vivo metabolic stability. Compound 2 maintained excellent cellular potency against CSNK2, submicromolar antiviral potency, and favorable solubility, and was remarkably selective for CSNK2 when screened against 192 kinases across the human kinome. We additionally present a co-crystal structure to support its on-target binding mode. In vivo, compound 2 was orally bioavailable, and demonstrated modest and transient inhibition of CSNK2, although antiviral activity was not observed, possibly attributed to its lack of prolonged CSNK2 inhibition.Keywords
All Related Versions
Funding Information
- Bayer AG (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Boehringer Ingelheim (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Bristol Myers Squibb (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Genentech (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Genome Canada through Ontario Genomics Institute (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Janssen (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Merck KGaA (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Pfizer (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Takeda (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- NC Biotech Center Institutional support grant (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- NIH Illuminating the Druggable Genome (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Department of Defense ALSRP award (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Rapidly Emerging Antiviral Drug Development Initiative (READDI) (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- Millennium Pharmaceuticals (Takeda) (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
- National Institutes of Health (OGI-196, 875510, 2018-IDG-1030, 1U24DK116204-01, AL190107, S10OD032476)
This publication has 46 references indexed in Scilit:
- Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3Bioorganic & Medicinal Chemistry Letters, 2024
- Host directed therapies: COVID-19 and beyondCurrent Research in Pharmacology and Drug Discovery, 2021
- Anti–SARS‐CoV‐2 Repurposing Drug Database: Clinical Pharmacology ConsiderationsCPT: Pharmacometrics & Systems Pharmacology, 2021
- Development of a potent and selective chemical probe for the pleiotropic kinase CK2Cell Chemical Biology, 2021
- Trends and strategies to combat viral infections: A review on FDA approved antiviral drugsInternational Journal of Biological Macromolecules, 2021
- Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitorEuropean Journal of Medicinal Chemistry, 2020
- A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory MiceCell, 2020
- The Global Phosphorylation Landscape of SARS-CoV-2 InfectionCell, 2020
- Medicinal chemistry strategies toward host targeting antiviral agentsMedicinal Research Reviews, 2020
- Coral: Clear and Customizable Visualization of Human Kinome DataCell Systems, 2018